Phreesia (PHR) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Phreesia (NYSE: PHR):

• 12/9/2025 – Phreesia had its price target lowered by analysts at Canaccord Genuity Group Inc. from $38.00 to $33.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Phreesia had its price target lowered by analysts at Citigroup Inc. from $34.00 to $29.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Phreesia had its price target lowered by analysts at JPMorgan Chase & Co. from $32.00 to $29.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – Phreesia is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $26.00 price target on the stock.
• 12/8/2025 – Phreesia had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
• 12/2/2025 – Phreesia had its price target raised by analysts at DA Davidson from $33.00 to $35.00. They now have a “buy” rating on the stock.
• 11/13/2025 – Phreesia is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $32.00 price target on the stock.
• 10/31/2025 – Phreesia had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity

In related news, CFO Balaji Gandhi sold 4,183 shares of Phreesia stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total transaction of $97,380.24. Following the transaction, the chief financial officer owned 99,125 shares in the company, valued at approximately $2,307,630. The trade was a 4.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Amy Beth Vanduyn sold 1,762 shares of the business’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $41,019.36. Following the completion of the transaction, the senior vice president directly owned 112,479 shares in the company, valued at $2,618,511.12. This trade represents a 1.54% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 26,174 shares of company stock worth $603,835. 5.50% of the stock is currently owned by corporate insiders.

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.